MediciNova, Inc. announced that the Phase II clinical trial of MN-166 in hospitalized COVID-19 patients at risk for developing acute respiratory distress syndrome has completed enrollment.
[MediciNova, Inc.]
6445212
BBBBBBBB
items
1
apa
0
default
asc
1
174021
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
